

See corresponding editorial on page 497.

Saturated fat, carbohydrate, and cardiovascular disease¹⁻⁴

Patty W Siri-Tarino, Qi Sun, Frank B Hu, and Ronald M Krauss

ABSTRACT

A focus of dietary recommendations for cardiovascular disease (CVD) prevention and treatment has been a reduction in saturated fat intake, primarily as a means of lowering LDL-cholesterol concentrations. However, the evidence that supports a reduction in saturated fat intake must be evaluated in the context of replacement by other macronutrients. Clinical trials that replaced saturated fat with polyunsaturated fat have generally shown a reduction in CVD events, although several studies showed no effects. An independent association of saturated fat intake with CVD risk has not been consistently shown in prospective epidemiologic studies, although some have provided evidence of an increased risk in young individuals and in women. Replacement of saturated fat by polyunsaturated or mono-unsaturated fat lowers both LDL and HDL cholesterol. However, replacement with a higher carbohydrate intake, particularly refined carbohydrate, can exacerbate the atherogenic dyslipidemia associated with insulin resistance and obesity that includes increased triglycerides, small LDL particles, and reduced HDL cholesterol. In summary, although substitution of dietary polyunsaturated fat for saturated fat has been shown to lower CVD risk, there are few epidemiologic or clinical trial data to support a benefit of replacing saturated fat with carbohydrate. Furthermore, particularly given the differential effects of dietary saturated fats and carbohydrates on concentrations of larger and smaller LDL particles, respectively, dietary efforts to improve the increasing burden of CVD risk associated with atherogenic dyslipidemia should primarily emphasize the limitation of refined carbohydrate intakes and a reduction in excess adiposity. *Am J Clin Nutr* 2010;91:502-9.

INTRODUCTION

Saturated fat intake has been linked to an increased risk of cardiovascular disease (CVD), and this effect is thought to be mediated primarily by increased concentrations of LDL cholesterol. Major dietary sources of saturated fatty acids in the United States are full-fat dairy products and red meat (1). Data from clinical trials have shown that substitution of polyunsaturated fat for saturated fat results in a reduced incidence of CVD (2-4); however, as described below, there is little evidence from such trials or from epidemiologic studies that a reduction in saturated fat intake below $\approx 9\%$ of total energy intake is associated with a reduced CVD risk. Recommendations for further reductions in saturated fat intake (eg, to $\leq 7\%$ of total energy) (5) are based primarily on the prediction of a progressive re-

duction in CVD risk associated with greater reductions in LDL cholesterol. However, from the standpoint of implementation, further reductions in saturated fat intake usually involve dietary prescriptions that include an increased proportion of carbohydrate (1, 5). For a large proportion of the population, however, the effect of higher-carbohydrate diets, particularly those enriched in refined carbohydrates, coupled with the rising incidence of overweight and obesity, creates a metabolic state that can favor a worsening of the atherogenic dyslipidemia that is characterized by elevated triglycerides, reduced HDL cholesterol, and increased concentrations of small, dense LDL particles (6, 7). Recent studies point to the beneficial effects of reducing carbohydrate intake, but not saturated fat, on this dyslipidemic state (8). In this review, consideration is given to the implications of these findings for dietary practices aimed at further reducing CVD risk.

CLINICAL TRIALS

As was previously summarized (9), randomized controlled dietary interventions that involved replacement of saturated fat with polyunsaturated fats resulted in reduced CVD risk in some, but not all, studies. The Finnish Mental Hospital Study (4), the

¹ From the Department of Atherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, CA (PWS-T and RMK); the Center for Excellence in Nutritional Genomics, University of California at Davis, Davis, CA (PWS-T and RMK); and the Departments of Nutrition (QS) and Epidemiology (FBH), Harvard School of Public Health, Boston, MA.

² The contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or the National Institutes of Health. Information on the NCRR is available at <http://www.ncrr.nih.gov/>.

³ Supported by grant UL1 RR024131-01 from the National Center for Research Resources, a component of the National Institutes of Health, and the National Institutes of Health Roadmap for Medical Research. Research relevant to this study was supported by the National Center for Minority Health and Health Disparities Center for Excellence in Nutritional Genomics and a grant from the National Dairy Council (PS-T and RMK). FBH was supported by NIH grant HL60712. QS was supported by a Postdoctoral Fellowship from Unilever Corporate Research.

⁴ Address correspondence to RM Krauss, Children's Hospital Oakland Research Institute, 5700 Martin Luther King Junior Way, Oakland, CA 94609. E-mail: rkrauss@chori.org.

Received April 15, 2008. Accepted for publication December 3, 2009.

First published online January 20, 2010; doi: 10.3945/ajcn.2008.26285.



Los Angeles Veterans Study (2), and the Oslo Diet Heart Study (3) all showed that a high polyunsaturated fat intake (13%, 16%, and 21% of total energy, respectively) in the context of saturated fat intake of $\approx 9\%$ and total fat intake of 35–40% of energy was associated with significant decreases in CVD events. In contrast, the British Medical Research Council Soy Oil Intervention (10) and the Minnesota Coronary Survey (11) showed nonsignificant effects of replacement of saturated fat with polyunsaturated fat on CVD.

Several clinical trials that involved reductions in saturated fat in the context of reduced total fat and increased carbohydrate intake showed no CVD risk benefit, but these studies may have been limited by a small sample size and/or a limited duration of follow-up (12, 13). Most recently, in the largest controlled dietary intervention trial to date, the Women's Health Initiative randomly assigned >48,000 postmenopausal women to a low-fat intervention or a comparison group in a free-living setting (14). Saturated fat intake was significantly lower in the intervention group than in the comparison group (means: 9.5% and 12.4%, respectively). Dietary polyunsaturated fat was also lower (difference = 1.5%), and dietary carbohydrate was higher (difference = 8.1%) in the intervention group than in the control group. After 6 y of follow-up, there were no differences between the groups in incidence of fatal and nonfatal coronary heart disease (CHD) and total CVD, including stroke.

In the Lyon Diet Heart Study, adoption of a "Mediterranean" style diet that included an increased intake of the omega-3 (n-3) fatty acid α -linolenic acid, a reduction in saturated fat to 8% compared with 11.7% of energy, and a modest increase in fiber and total carbohydrate was associated with a 72% reduction in recurrent CHD events in patients with prior myocardial infarction (15, 16). Secondary analyses of plasma fatty acid composition in this study indicated that the CHD benefit was most strongly correlated with increased α -linolenic acid. There were no significant differences in traditional risk factors, including LDL cholesterol, between the groups, which supported the hypothesis that the CHD benefit could be attributed, at least in part, to increased omega-3 fatty acid intakes.

A program of comprehensive lifestyle changes, including a vegetarian diet very low in total fat, smoking cessation, stress management training, and moderate exercise, has been reported to lead to a regression of coronary atherosclerosis after 1 y (17) and 5 y (18) of intervention in comparison with a usual-care control group. In a separate study that used a similar program of risk factor modification but also included group support, the size and severity of myocardial perfusion abnormalities and coronary artery stenoses decreased in the intervention group but increased in the usual-care control group (19). Despite their effectiveness, the multifactorial nature of these interventions prevented the attribution of CVD benefit to any specific factor, including saturated fat intake.

PROSPECTIVE COHORT STUDIES

A meta-analysis including 16 prospective observational cohort studies (20–35) that assessed the relation between dietary saturated fat and CHD appears in this issue of the Journal (36). Although some studies reported significant associations either in the entire cohort (28) or in subgroups (21, 22, 35), the overall risk ratio for CHD, after adjustment for relevant covariates, was not

significantly increased (risk ratio = 1.07). A study evaluating saturated fat intake in childhood showed no association with adult CHD mortality (37). Mozaffarian et al (38) showed dietary saturated fat to be inversely associated with coronary atherosclerosis progression in a cohort of postmenopausal women. More recently, another study showed positive associations between saturated fat in plasma phospholipids and CHD mortality (39). However, these fatty acids are not necessarily valid biomarkers for dietary saturated fat, because they can be endogenously synthesized (40, 41). Finally, there is evidence from some studies (42, 43) that saturated fat intake may be inversely related to ischemic and/or hemorrhagic stroke, but a meta-analysis including results from 6 other studies (24, 27, 29, 44–46) did not yield a statistically significant risk reduction (36). Overall, despite the conventional wisdom that reduced dietary saturated fat intake is beneficial for cardiovascular health, the evidence for a positive, independent association is lacking (36). These conclusions are consistent with a recent review of the relation between dietary patterns and nutrient factors and CVD risk (47).

ROLE OF OTHER NUTRIENTS IN CVD

Replacement of saturated fat with carbohydrate was not significantly associated with a reduced risk of CHD (relative risk: 1.17; 95% CI: 0.97, 1.41) (48). Consistent with this analysis, a low-carbohydrate diet score (a higher score being indicative of higher protein and fat intakes and a lower intake of carbohydrate) in the same cohort was not associated with increased CHD risk in women (49).

Type of dietary carbohydrate, as measured by the glycemic index or glycemic load, has also been suggested to be a relevant determinant of CHD risk in some (50, 51), but not all (52, 53), studies. Glycemic index ranks carbohydrates according to their effects on blood glucose concentrations, and glycemic load is calculated from glycemic index, carbohydrate content, and actual or estimated intake of food items. High glycemic load from refined carbohydrates was shown to be associated with an increased CHD risk independently of known risk factors in the Nurses' Health Study (51) and was more recently shown to be associated with an increased risk of CHD in a prospective cohort study of >15,000 middle-aged women (50). In line with these observations, replacement of saturated fat with monounsaturated fat rather than carbohydrate was associated with a decreased CHD risk in patients with diabetes (54). A recent meta-analysis showed borderline significant associations of increased glycemic index with heart disease (relative risk: 1.25; 95% CI: 1.00, 1.56) (55). Nonetheless, given the relatively limited number of studies that have been carried out to evaluate the relation of glycemic index and/or load with CVD risk, further research is needed in this area.

DIETARY SATURATED FAT AND CVD RISK FACTORS

Lipids and lipoproteins

The effect of dietary saturated fat on plasma lipoproteins that is felt to most strongly affect CVD risk is elevated LDL-cholesterol concentrations (56). Replacement of saturated fat with polyunsaturated fat has been shown to decrease total, LDL, and HDL cholesterol (57). On the basis of analyses of the effects of substituting individual categories of fatty acids for carbohydrates,



LDL cholesterol can be reduced by both monounsaturated and polyunsaturated fats, with an apparently greater effect of the latter (56). Importantly, the effects of saturated fat on lipids and lipoproteins may be modulated by the content and/or availability of polyunsaturated fatty acids, such that saturated fat only affects LDL cholesterol if the polyunsaturated fat intake is below a threshold level ($\approx 5\%$ of energy) (58, 59). LDL cholesterol as well as total cholesterol and apolipoprotein B were not different between women who consumed diets high or low in saturated fat but with similar ratios of polyunsaturated to saturated fat (P:S) (60). Similarly, the amount of cholesterol consumed in the diet has been shown to modulate effects of saturated fat such that, at lower intakes of cholesterol, the effect of saturated fat on LDL cholesterol was minimal compared with significant LDL-cholesterol raising effects at higher concentrations of dietary cholesterol (61).

Replacement of saturated with polyunsaturated fatty acids in the diets of hyperlipidemic subjects has been reported to lower the LDL-cholesterol production rate (62, 63), although an increase in clearance rate, possibly because of an increased LDL receptor activity, has been reported (64). Replacement of saturated fat with polyunsaturated (65), but not monounsaturated (66), fat has also been shown to decrease coronary atherosclerosis in African green monkeys.

Substitution of saturated fat for carbohydrate results in increases in HDL cholesterol, with no net effect on the total:HDL-cholesterol ratio (67). On the other hand, whereas smaller increases in HDL cholesterol are observed with substitution of monounsaturated and polyunsaturated fats for carbohydrate, these dietary changes result in significant reductions in the total:HDL-cholesterol ratio (67). There are differences between individual types of saturated fatty acids with regard to effects on LDL and HDL cholesterol (67). Specifically, there is a progressively smaller LDL-cholesterol-raising effect with substitution for carbohydrate of saturated fatty acids of increasing chain length, with the largest increase observed for lauric acid (12 carbons), and no significant increase with stearic acid (18 carbons). However, lauric acid substitution also results in the greatest increase in HDL cholesterol, such that there is significant lowering of the total:HDL-cholesterol ratio (67).

In recent years, there has been increasing concern regarding dietary effects on dyslipidemia, characterized by elevated triglycerides, low concentrations of HDL cholesterol, and increased concentrations of small, dense LDL particles (68). This metabolic profile is considered to be a major contributor to increased CVD risk in patients with the metabolic syndrome, insulin resistance, and type 2 diabetes. Both increased adiposity (69) and higher carbohydrate intakes (6) have been shown to increase the magnitude of each of the components of atherogenic dyslipidemia. In hypercholesterolemic and combined hyperlipidemic patients, fat restriction to $<25\%$ and carbohydrate intakes $>60\%$ was associated with similar adverse changes in lipids (increased triglyceride and reduced HDL cholesterol) with no further reductions in LDL cholesterol; furthermore, high-carbohydrate feeding led to increased plasma concentrations of palmitate, thus negating the effects of further reductions in saturated fat on palmitate concentrations (70). The induced adverse effects on HDL cholesterol and triglyceride may counteract any benefits of reductions in dietary fat on CVD in men (71). Because HDL cholesterol and triglycerides are stronger risk factors in women,

such lipid changes result in a predicted increase in coronary disease incidence in this subgroup (71).

In several studies in which weight loss was induced by very-low-carbohydrate diets, it was observed that LDL-cholesterol concentrations and total:HDL-cholesterol ratios did not increase despite the high intakes of saturated fat on these diets (72, 73). However, these studies did not distinguish between the effects of weight loss and changes in diet composition. We recently conducted a study to evaluate the effects of dietary carbohydrate restriction (from 54% to 26%) with low and high saturated fat (derived primarily from dairy products) in the context of both weight loss and weight stability (8). Carbohydrate restriction under weight-stable conditions reduced total:HDL cholesterol, apolipoprotein B, and the mass of small, dense LDL particles (Figure 1). Weight loss without restriction of carbohydrates led to similar changes (8).

The type of dietary carbohydrate consumed may affect lipid and lipoprotein profiles (74, 75), although a thorough analysis of the evidence for this hypothesis is beyond the scope of this review. Recent studies showed that, compared with dietary saturated fat, the saturated fat to fiber ratio was a stronger predictor of lipoprotein response in persons consuming beef or vegetarian diets (76). Furthermore, the DASH (Dietary Approaches to Stop Hypertension) diet, which reduces saturated fat to 7% and emphasizes an increase in complex carbohydrates rather than simple carbohydrates, lowered total, LDL, and HDL cholesterol without increasing triglyceride concentrations (77).

Effects of saturated fat on LDL and HDL size and composition

LDL and HDL particles of different sizes and compositions derive from many metabolic pathways, and smaller and more dense LDL particles have been implicated as being more strongly involved in atherosclerotic CVD than larger LDL particles, as




FIGURE 1. Mean (\pm SEM) effects of variation in dietary carbohydrate and saturated fat on LDL subclasses. A cohort of 178 men were randomly assigned to 1 of 4 diet groups: diets with varying carbohydrate contents (54%, 39%, or 26% of total energy) and a low saturated fat content (\bullet , 8% of total energy derived primarily from dairy products) or a diet with a relatively low carbohydrate (26%) and a high saturated fat content (\square , 15% of total energy) (8). In the context of the 26% carbohydrate diet, high dietary saturated fat was associated with increases in large and medium LDL, but not with small LDL, relative to diets with a lower saturated fat content. Data points represent biochemical profiles for each of the 4 dietary groups. Values are the total lipoprotein mass as measured by analytic ultracentrifugation.



reviewed elsewhere (78). The reduction in LDL cholesterol known to occur with a decreased saturated fat intake appears to be specific to larger more buoyant particles (79). In persons placed on a baseline high-saturated-fat diet and then switched to a diet high in monounsaturated or polyunsaturated fat, a small but significant reduction in LDL particle size was observed (80). Furthermore, we recently showed that the lower concentrations of small, dense LDL particles resulting from a reduced carbohydrate intake (26% compared with 54% of energy) were similar with diets high (15%) or low (8%) in saturated fat derived primarily from dairy products. In contrast, the higher saturated fat intake raised concentrations of larger, more cholesterol-enriched LDL particles, thus offsetting the reduction in total LDL concentrations that was observed with lower saturated fat intake (8) (Figure 1). These effects were apparent after 3 wk and were independent of weight loss.

Dietary intake of fatty acids can also influence lipoprotein composition. In the acute postprandial response to meals high in saturated fat, high in polyunsaturated fat, or low in total fat, no changes were observed in LDL triglyceride or cholesterol composition, ie, there were no changes in density (77). However, the P:S ratio in the LDL surface monolayer was higher after a meal enriched in polyunsaturated fat than in a meal enriched in saturated fat (81). In contrast, the HDL reduction associated with decreased saturated fat intakes has not been associated with changes in HDL particle composition (82). There is evidence that dietary regimens that lead to the enrichment of LDL with 18:2 polyunsaturated fatty acids are associated with an increased susceptibility of LDL to oxidation (83, 84), an effect associated with an increased CHD risk (85). On the other hand, extensive studies in animal models, particular monkeys, have shown that dietary enrichment of LDL with polyunsaturated fats was associated with reduced atherosclerosis compared with either monounsaturated or saturated fat (86). In these studies, atherosclerosis was associated with the diet-induced enrichment of LDL with cholesteryl oleate. Notably, in humans, the risk of stroke has been related to both the saturated and monounsaturated fatty acid content of plasma cholesteryl esters, which further supports the possibility that the dietary intake of these fatty acids may influence CVD risk by altering cholesteryl ester composition (87).

Factors affecting variation in lipoprotein response to saturated fat

There is considerable interindividual variability in the lipoprotein response to variations in saturated fat intake, and this is related to some extent to variation in response to dietary cholesterol, which suggests a role for intrinsic differences in the regulation of lipid metabolism (88, 89). Baseline LDL-cholesterol concentrations appear to be strongly related to dietary responsiveness, and it was reported that this may be related to differences in the fractional catabolic rates of LDL (90). Other factors that have been reported to be associated with a reduced LDL response to reductions in saturated fat include increased BMI (91), insulin resistance (92), and female sex (93). A relation between triglyceride metabolism and the LDL response to diet is supported by the finding that saturated fats increase LDL cholesterol in normotriglyceridemic but not in hypertriglyceridemic persons (94). Low birth weight has been associated with reduced HDL cholesterol in response to saturated fat in men (95). Genetic factors may also contribute to variability in the dietary response

to saturated fat (96–98). Among these, the apoE4 isoform, which is associated with increased plasma LDL cholesterol in comparison with the more common apoE3 isoform, has been most consistently found to be predictive of a greater LDL-cholesterol reduction in response to diet (99, 100).

Finally, there is little information from clinical trials addressing the possibility that the effects of saturated fat on CVD risk factors may be modified by the foods in which they are contained. In this regard, it is of interest that the effects of dairy-derived fat on lipids and lipoproteins have been reported to differ between specific types of dairy food sources (101).

Blood pressure

The effect of saturated fat on blood pressure has not been definitively established, although a study in 162 healthy persons showed that a diet high in monounsaturated fat decreased blood pressure, whereas a diet high in saturated fat led to no change in blood pressure (102). In the Dietary Intervention Study in children, total fat, but not saturated fat, was positively associated with systolic blood pressure, and total and monounsaturated fat, but not saturated fat, was associated with diastolic blood pressure when all nutrients were considered simultaneously in a regression model (103).

More recently, a 1-y weight-loss study that compared the effects of a very-low-carbohydrate, high-saturated-fat diet with those of an isocaloric high-carbohydrate, low-fat diet showed comparable reductions in weight and blood pressure (104). In contrast, a prospective study in children aged from 7 mo to 15 y showed that in those receiving low-saturated-fat counseling throughout childhood, diastolic and systolic blood pressure was 1 mm Hg lower than in control children (105); however, polyunsaturated fat intake was also higher in this group, as was protein intake, which thereby limited the ability to attribute the observed reduction in blood pressure specifically to saturated fat.

Insulin sensitivity

Studies in animal models have indicated that insulin sensitivity is impaired by saturated fat intake and is improved by omega-3 fatty acids (106, 107). Mechanistic studies have suggested that saturated fatty acids impair insulin sensitivity by reducing adiponectin secretion and impairing insulin signaling pathways required for glucose uptake (108) in white adipose tissue. Saturated fatty acids have also been shown to increase lipid accumulation in rat muscle (109).

Some human observational studies have reported positive associations between saturated fat intake and hyperinsulinemia that were independent of body fat (110, 111). In obese patients with type 2 diabetes, consumption of diets high in saturated and *trans* fats for 6 wk were associated with increased postprandial insulinemia compared with baseline or diets rich in monounsaturated fat (112). However, in the Nurses' Health Study, total, saturated, and monounsaturated fats were not associated with risk of type 2 diabetes, whereas polyunsaturated fats decreased the risk and *trans* fats increased the risk (113). Similarly, in the Health Professionals Follow-Up Study, saturated fat was not associated with risk of type 2 diabetes after adjustment for BMI (114). Furthermore, in most human intervention studies, changes in dietary fat quality had no effects on insulin sensitivity (106, 115). However, the effect of saturated fat on insulin



sensitivity may be modulated by the total amount of fat in the diet (116). In a randomized clinical trial of 162 healthy persons, no differences in insulin sensitivity were observed between persons consuming saturated fat-enriched or monounsaturated fat-enriched diets when total fat intake represented >37% of total energy; in contrast, in persons who consumed lower total fat intakes, saturated fat led to decreased insulin sensitivity compared with monounsaturated fat (116). In other studies, there have been no consistent effects on insulin sensitivity of variations in total fat intake between 20% and 40% of total energy intake without changes in fatty acid composition (107, 117).

Thrombosis, inflammatory markers, and vascular function

Data from experiments in macrophage cell lines from animals (118, 119) and humans (120) have shown that saturated fats, but not unsaturated fats, can induce the activation of nuclear factor- κ B (NF- κ B) and the expression of Cox2 and other inflammatory markers, including interleukin-6 and tumor necrosis factor- α (TNF- α)—an effect thought to be mediated by the Toll-like receptor 4 (118, 119). More recently, however, stimulation of Toll-like receptor 4 has been attributed to liposaccharide and lipopeptide contamination of bovine serum albumin, a commonly used reagent in cell culture preparations, rather than saturated fatty acids (121). Nonetheless, there is a growing body of evidence from cellular and animal studies that supports the proinflammatory effects of saturated fat, as reviewed extensively elsewhere (108).

In a randomized controlled human feeding trial, Baer et al (122) showed that stearic acid, but not a combination of lauric, myristic, and palmitic acids, increased fibrinogen concentrations relative to controls who consumed carbohydrate. No effects on C-reactive protein, interleukin-6, or E-selectin were observed during consumption of saturated fatty acids compared with carbohydrate. Oleic acid consumption, however, was associated with decreased interleukin-6 and E-selectin relative to consumption of saturated fat (122). In cells obtained from healthy subjects who were given a cream challenge, a delay in the peak of reactive oxygen species as well as a protracted increase in oxidatively damaged lipids compared with challenges with protein or glucose (123) was observed.

An olive oil meal, high in monounsaturated fat, did not lead to NF- κ B activation compared with meals of butter or walnuts, which showed comparable responses; notably, the saturated fat contents of the olive oil and walnut meals were similar (124). In a recent study, a butter meal led to increased TNF- α mRNA compared with walnut or olive oil meals, whereas both the butter and olive oil meals led to increased interleukin-6 mRNA compared with the walnut meal (125); however, no differences in plasma concentrations of the inflammatory markers were observed (125).

Iso-caloric reductions in total (from \approx 35% to \approx 15%) and saturated fat (from \approx 15% to \approx 6%) with replacement by carbohydrate were not associated with changes in plasma concentrations of C-reactive protein in 2 independent diet studies (126, 127). In a double-blind crossover study in 19 persons, consumption of butter over 32 d was not associated with an increased inflammatory cytokine response relative to soybean oil (128). In the same study, however, butter consumption was associated with a reduced cellular immune response as measured by delayed type hypersensitivity (128). Interestingly, saturated fat, but not unsaturated fat, was able to reverse ethanol-induced

liver injury, including fibrosis, with reductions in Cox2 and TNF- α in rats (129).

Saturated fat may also affect vascular function, perhaps by increasing the selective uptake of cholesterol in the arterial wall, resulting in increased atherogenesis in mouse models (130). In the acute postprandial phase following a meal enriched in saturated or polyunsaturated fat, HDL collected from individuals after a coconut meal compared with a safflower or unsaturated fat meal was associated with a 50–70% increase in intercellular adhesion molecule and vascular cell adhesion molecule (131). Attribution of this effect specifically to the saturated fat of the coconut meal may, however, be confounded by the high concentrations of tocopherol found in coconut oil (132).

CONCLUSIONS

Evidence from clinical trials and prospective epidemiologic studies support the cardiovascular benefit of substituting polyunsaturated fat for saturated fat, but the benefit of reducing saturated fat below \approx 9% has not been evaluated. The benefits of a further reduction in saturated fat to $<$ \approx 9% are inferred from extrapolation of epidemiologic data on the effects on LDL cholesterol beyond the range for which the data are informative (5).

Studies of atherogenic lipoprotein concentrations and properties have raised questions about the benefit of lowering saturated fat intakes by increasing carbohydrate intake, which can induce atherogenic dyslipidemia, and the benefit of increasing monounsaturated fat intakes, which does not lead to improvements in the properties of LDL particles that are associated with atherosclerosis in animal models, although substitution with monounsaturated fat rather than carbohydrate has been shown to reduce the ratio of total and LDL cholesterol to HDL cholesterol. Moreover, whereas it is not known whether diet-induced increases in HDL cholesterol confer protection against CVD risk that would be inferred from epidemiologic data, this effect of dietary saturated fat requires consideration when assessing its net effect on CVD risk. In contrast, recent evidence indicates that limitations in carbohydrate intake can improve all features of atherogenic dyslipidemia. Finally, clinical studies have not yielded consistent evidence for adverse effects of saturated fat on CVD risk factors other than LDL cholesterol, although reduced insulin sensitivity and increased inflammation have been reported in animal and cellular studies.

Thus, given the changing landscape of CVD risk factors and the increasing importance of the atherogenic dyslipidemia associated with obesity, insulin resistance, and type 2 diabetes, the relative effect of dietary saturated fat on CVD risk requires reevaluation. This is of particular concern with regard to the implications of further restrictions in total and saturated fat beyond prevailing US dietary guidelines, which call for levels no higher than 10% of total energy, and the recognition that subsets of the population may not benefit, and may even be harmed, by the substitution of high intakes of carbohydrates, especially refined carbohydrates, for fat in the diet. Particularly given the differential effects of dietary saturated fats and carbohydrates on concentrations of larger and smaller LDL particles, respectively, dietary efforts to improve the increasing burden of CVD risk associated with atherogenic dyslipidemia should primarily emphasize the limitation of refined carbohydrate intakes and a reduction in excess adiposity.



The authors' responsibilities were as follows—PWS-T: wrote the manuscript; FBH and QS: provided significant advice and consultation; and RMK: wrote and provided significant advice related to the manuscript. None of the authors reported a conflict of interest.

REFERENCES

1. US Department of Health and Human Services. Dietary guidelines for Americans 2005. Washington, DC: USDA, 2005.
2. Dayton S, Pearce M, Hashimoto S, et al. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. *Circulation* 1969;40(suppl II):II-1-63.
3. Leren P. The Oslo Diet-Heart Study: eleven-year report. *Circulation* 1970;42:935-42.
4. Turpeinen O, Karvonen MJ, Pekkarinen M, Miettinen M, Elosuo R, Paavilainen E. Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study. *Int J Epidemiol* 1979;8:99-118.
5. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. *Circulation* 2006;114:82-96.
6. Parks EJ, Hellerstein MK. Carbohydrate-induced hypertriglycerolemia: historical perspective and review of biological mechanisms. *Am J Clin Nutr* 2000;71:412-33.
7. Siri PW, Krauss RM. Influence of dietary carbohydrate and fat on LDL and HDL particle distributions. *Curr Atheroscler Rep* 2005;7:455-9.
8. Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT. Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. *Am J Clin Nutr* 2006;83:1025-31, quiz 1205.
9. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. *JAMA* 2002;288:2569-78.
10. Morris JN, Ball KP, Antonis A, et al. Controlled trial of soya-bean oil in myocardial infarction. *Lancet* 1968;292:693-9.
11. Frantz ID Jr, Dawson EA, Ashman PL, et al. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. *Arteriosclerosis* 1989;9:129-35.
12. Ball KP, Hanington E, McAllen P, et al. Low fat diet in myocardial infarction: a controlled trial. *Lancet* 1965;286:501-4.
13. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction: diet and reinfarction trial (DART). *Lancet* 1989;2:757-61.
14. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA* 2006;295:655-66.
15. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. *Lancet* 1994;343:1454-9.
16. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation* 1999;99:779-85.
17. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. *Lancet* 1990;336:129-33.
18. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. *JAMA* 1998;280:2001-7.
19. Gould KL, Ornish D, Scherwitz L, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. *JAMA* 1995;274:894-901.
20. Ascherio A, Rimm EB, Giovannucci EL, Spiegelman D, Stampfer M, Willett WC. Dietary fat and risk of coronary heart disease in men: cohort follow up study in the United States. *BMJ* 1996;313:84-90.
21. Boniface DR, Tefft ME. Dietary fats and 16-year coronary heart disease mortality in a cohort of men and women in Great Britain. *Eur J Clin Nutr* 2002;56:786-92.
22. Esrey KL, Joseph L, Grover SA. Relationship between dietary intake and coronary heart disease mortality: lipid research clinics prevalence follow-up study. *J Clin Epidemiol* 1996;49:211-6.
23. Fehily AM, Yarnell JW, Sweetnam PM, Elwood PC. Diet and incident ischaemic heart disease: the Caerphilly Study. *Br J Nutr* 1993;69:303-14.
24. Goldbourt U, Yaari S, Medalie JH. Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees. A 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study. *Cardiology* 1993;82:100-21.
25. Jakobsen MU, Overvad K, Dyerberg J, Schroll M, Heitmann BL. Dietary fat and risk of coronary heart disease: possible effect modification by gender and age. *Am J Epidemiol* 2004;160:141-9.
26. Kushi LH, Lew RA, Stare FJ, et al. Diet and 20-year mortality from coronary heart disease. The Ireland-Boston Diet-Heart Study. *N Engl J Med* 1985;312:811-8.
27. Leosdottir M, Nilsson PM, Nilsson JA, Mansson H, Berglund G. Dietary fat intake and early mortality patterns: data from The Malmo Diet and Cancer Study. *J Intern Med* 2005;258:153-65.
28. Mann JI, Appleby PN, Key TJ, Thorogood M. Dietary determinants of ischaemic heart disease in health conscious individuals. *Heart* 1997;78:450-5.
29. McGee DL, Reed DM, Yano K, Kagan A, Tillotson J. Ten-year incidence of coronary heart disease in the Honolulu Heart Program. Relationship to nutrient intake. *Am J Epidemiol* 1984;119:667-76.
30. Oh K, Hu FB, Manson JE, Stampfer MJ, Willett WC. Dietary fat intake and risk of coronary heart disease in women: 20 years of follow-up of the nurses' health study. *Am J Epidemiol* 2005;161:672-9.
31. Pietinen P, Ascherio A, Korhonen P, et al. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. *Am J Epidemiol* 1997;145:876-87.
32. Posner BM, Cobb JL, Belanger AJ, Cupples LA, D'Agostino RB, Stokes J III. Dietary lipid predictors of coronary heart disease in men. The Framingham Study. *Arch Intern Med* 1991;151:1181-7.
33. Shekelle RB, Shryock AM, Paul O, et al. Diet, serum cholesterol, and death from coronary heart disease. The Western Electric study. *N Engl J Med* 1981;304:65-70.
34. Tucker KL, Hallfrisch J, Qiao N, Muller D, Andres R, Fleg JL. The combination of high fruit and vegetable and low saturated fat intakes is more protective against mortality in aging men than is either alone: the Baltimore Longitudinal Study of Aging. *J Nutr* 2005;135:556-61.
35. Xu J, Eilat-Adar S, Loria C, et al. Dietary fat intake and risk of coronary heart disease: the Strong Heart Study. *Am J Clin Nutr* 2006;84:894-902.
36. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. *Am J Clin Nutr* 2010;91:535-46.
37. Ness AR, Maynard M, Frankel S, et al. Diet in childhood and adult cardiovascular and all cause mortality: the Boyd Orr cohort. *Heart* 2005;91:894-8.
38. Mozaffarian D, Rimm EB, Herrington DM. Dietary fats, carbohydrate, and progression of coronary atherosclerosis in postmenopausal women. *Am J Clin Nutr* 2004;80:1175-84.
39. Clarke R, Shipley M, Armitage J, Collins R, Harris W. Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servants. *Br J Nutr* 2009;102:279-84.
40. Ma J, Folsom AR, Shahar E, Eckfeldt JH. Plasma fatty acid composition as an indicator of habitual dietary fat intake in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. *Am J Clin Nutr* 1995;62:564-71.
41. Sun Q, Ma J, Campos H, Hankinson SE, Hu FB. Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. *Am J Clin Nutr* 2007;86:74-81.
42. Gillman MW, Cupples LA, Millen BE, Ellison RC, Wolf PA. Inverse association of dietary fat with development of ischemic stroke in men. *JAMA* 1997;278:2145-50.
43. Iso H, Sato S, Kitamura A, Naito Y, Shimamoto T, Komachi Y. Fat and protein intakes and risk of intraparenchymal hemorrhage among middle-aged Japanese. *Am J Epidemiol* 2003;157:32-9.
44. He K, Merchant A, Rimm EB, et al. Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study. *BMJ* 2003;327:777-82.
45. Iso H, Stampfer MJ, Manson JE, et al. Prospective study of fat and protein intake and risk of intraparenchymal hemorrhage in women. *Circulation* 2001;103:856-63.
46. Sauvaget C, Nagano J, Hayashi M, Yamada M. Animal protein, animal fat, and cholesterol intakes and risk of cerebral infarction mortality in the adult health study. *Stroke* 2004;35:1531-7.
47. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Arch Intern Med* 2009;169:659-69.



48. Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. *N Engl J Med* 1997;337:1491-9.
49. Halton TL, Willett WC, Liu S, et al. Low-carbohydrate-diet score and the risk of coronary heart disease in women. *N Engl J Med* 2006;355:1991-2002.
50. Beulens JW, de Bruijne LM, Stolk RP, et al. High dietary glycaemic load and glycaemic index increase risk of cardiovascular disease among middle-aged women: a population-based follow-up study. *J Am Coll Cardiol* 2007;50:14-21.
51. Liu S, Willett WC, Stampfer MJ, et al. A prospective study of dietary glycaemic load, carbohydrate intake, and risk of coronary heart disease in US women. *Am J Clin Nutr* 2000;71:1455-61.
52. Levitan EB, Mittleman MA, Hakansson N, Wolk A. Dietary glycaemic index, dietary glycaemic load, and cardiovascular disease in middle-aged and older Swedish men. *Am J Clin Nutr* 2007;85:1521-6.
53. van Dam RM, Visscher AW, Feskens EJ, Verhoef P, Kromhout D. Dietary glycaemic index in relation to metabolic risk factors and incidence of coronary heart disease: the Zutphen Elderly Study. *Eur J Clin Nutr* 2000;54:726-31.
54. Tanasescu M, Cho E, Manson JE, Hu FB. Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. *Am J Clin Nutr* 2004;79:999-1005.
55. Barclay AW, Petocz P, McMillan-Price J, et al. Glycaemic index, glycaemic load, and chronic disease risk: a meta-analysis of observational studies. *Am J Clin Nutr* 2008;87:627-37.
56. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins: a meta-analysis of 27 trials. *Arterioscler Thromb* 1992;12:911-9.
57. Hodson L, Skeaff CM, Chisholm WA. The effect of replacing dietary saturated fat with polyunsaturated or monounsaturated fat on plasma lipids in free-living young adults. *Eur J Clin Nutr* 2001;55:908-15.
58. Hayes KC, Khosla P, Hajri T, Pronczuk A. Saturated fatty acids and LDL receptor modulation in humans and monkeys. *Prostaglandins Leukot Essent Fatty Acids* 1997;57:411-8.
59. Wijendran V, Hayes KC. Dietary n-6 and n-3 fatty acid balance and cardiovascular health. *Annu Rev Nutr* 2004;24:597-615.
60. Muller H, Lindman AS, Brantsaeter AL, Pedersen JI. The serum LDL/HDL cholesterol ratio is influenced more favorably by exchanging saturated with unsaturated fat than by reducing saturated fat in the diet of women. *J Nutr* 2003;133:78-83.
61. Fielding CJ, Havel RJ, Todd KM, et al. Effects of dietary cholesterol and fat saturation on plasma lipoproteins in an ethnically diverse population of healthy young men. *J Clin Invest* 1995;95:611-8.
62. Cortese C, Levy Y, Janus ED, et al. Modes of action of lipid-lowering diets in man: studies of apolipoprotein B kinetics in relation to fat consumption and dietary fatty acid composition. *Eur J Clin Invest* 1983;13:79-85.
63. Turner JD, Le NA, Brown WV. Effect of changing dietary fat saturation on low-density lipoprotein metabolism in man. *Am J Physiol* 1981;241:E57-63.
64. Shepherd J, Packard CJ, Grundy SM, Yeshurun D, Gotto AM Jr, Taunton OD. Effects of saturated and polyunsaturated fat diets on the chemical composition and metabolism of low density lipoproteins in man. *J Lipid Res* 1980;21:91-9.
65. Rudel LL, Johnson FL, Sawyer JK, Wilson MS, Parks JS. Dietary polyunsaturated fat modifies low-density lipoproteins and reduces atherosclerosis of nonhuman primates with high and low diet responsiveness. *Am J Clin Nutr* 1995;62:463S-70S.
66. Rudel LL, Parks JS, Sawyer JK. Compared with dietary monounsaturated and saturated fat, polyunsaturated fat protects African green monkeys from coronary artery atherosclerosis. *Arterioscler Thromb Vasc Biol* 1995;15:2101-10.
67. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr* 2003;77:1146-55.
68. Krauss RM, Siri PWB. Metabolic abnormalities: triglyceride and low-density lipoprotein. *Endocrinol Metab Clin North Am* 2004;33:405-15.
69. Grundy SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. *Clin Cornerstone* 2006;8(suppl 1):S21-7.
70. Knopp RH, Retzlaff B, Walden C, Fish B, Buck B, McCann B. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects. *Proc Soc Exp Biol Med* 2000;225:191-9.
71. Sacks FM, Katan M. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. *Am J Med* 2002;113(suppl 9B):13S-24S.
72. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. *N Engl J Med* 2003;348:2082-90.
73. Yancy WS Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. *Ann Intern Med* 2004;140:769-77.
74. Pelkman CL. Effects of the glycaemic index of foods on serum concentrations of high-density lipoprotein cholesterol and triglycerides. *Curr Atheroscler Rep* 2001;3:456-61.
75. Jenkins DJ, Kendall CW, Augustin LS, Vuksan V. High-complex carbohydrate or lente carbohydrate foods? *Am J Med* 2002;113(suppl 9B):30S-7S.
76. Haub MD, Wells AM, Campbell WW. Beef and soy-based food supplements differentially affect serum lipoprotein-lipid profiles because of changes in carbohydrate intake and novel nutrient intake ratios in older men who resistive-train. *Metabolism* 2005;54:769-74.
77. Obarzanek E, Sacks FM, Vollmer WM, et al. Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. *Am J Clin Nutr* 2001;74:80-9.
78. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. *J Lipid Res* 2002;43:1363-79.
79. Dreon DM, Fernstrom HA, Campos H, Blanche P, Williams PT, Krauss RM. Change in dietary saturated fat intake is correlated with change in mass of large low-density-lipoprotein particles in men. *Am J Clin Nutr* 1998;67:828-36.
80. Kratz M, Gulbahce E, von Eckardstein A, et al. Dietary mono- and polyunsaturated fatty acids similarly affect LDL size in healthy men and women. *J Nutr* 2002;132:715-8.
81. Callow J, Summers LK, Bradshaw H, Frayn KN. Changes in LDL particle composition after the consumption of meals containing different amounts and types of fat. *Am J Clin Nutr* 2002;76:345-50.
82. Berglund L, Oliver EH, Fontanez N, et al. HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects. *Am J Clin Nutr* 1999;70:992-1000.
83. Yu-Poth S, Etherton TD, Reddy CC, et al. Lowering dietary saturated fat and total fat reduces the oxidative susceptibility of LDL in healthy men and women. *J Nutr* 2000;130:2228-37.
84. Reaven PD, Grasse BJ, Tribble DL. Effects of linoleate-enriched and oleate-enriched diets in combination with alpha-tocopherol on the susceptibility of LDL and LDL subfractions to oxidative modification in humans. *Arterioscler Thromb* 1994;14:557-66.
85. Galassetti P, Pontello A. Dietary effects on oxidation of low-density lipoprotein and atherogenesis. *Curr Atheroscler Rep* 2006;8:523-9.
86. Rudel LL, Haines J, Sawyer JK, Shah R, Wilson MS, Carr TP. Hepatic origin of cholesteryl oleate in coronary artery atherosclerosis in African green monkeys. Enrichment by dietary monounsaturated fat. *J Clin Invest* 1997;100:74-83.
87. Wiberg B, Sundstrom J, Arnlov J, et al. Metabolic risk factors for stroke and transient ischemic attacks in middle-aged men: a community-based study with long-term follow-up. *Stroke* 2006;37:2898-903.
88. Beynen AC, Katan MB, Van Zutphen LF. Hypo- and hyperresponders: individual differences in the response of serum cholesterol concentration to changes in diet. *Adv Lipid Res* 1987;22:115-71.
89. Katan MB, van Gastel AC, de Rover CM, van Montfort MA, Knuiman JT. Differences in individual responsiveness of serum cholesterol to fat-modified diets in man. *Eur J Clin Invest* 1988;18:644-7.
90. Denke MA. Review of human studies evaluating individual dietary responsiveness in patients with hypercholesterolemia. *Am J Clin Nutr* 1995;62:471S-7S.
91. Jansen S, Lopez-Miranda J, Salas J, et al. Plasma lipid response to hypolipidemic diets in young healthy non-obese men varies with body mass index. *J Nutr* 1998;128:1144-9.
92. Lefevre M, Champagne CM, Tulley RT, Rood JC, Most MM. Individual variability in cardiovascular disease risk factor responses to low-fat and low-saturated-fat diets in men: body mass index, adiposity, and insulin resistance predict changes in LDL cholesterol. *Am J Clin Nutr* 2005;82:957-63, quiz 1145-6.
93. Weggemans RM, Zock PL, Urgert R, Katan MB. Differences between men and women in the response of serum cholesterol to dietary changes. *Eur J Clin Invest* 1999;29:827-34.



94. Knopp RH, Fish B, Dowdy A, et al. A moderate-fat diet for combined hyperlipidemia and metabolic syndrome. *Curr Atheroscler Rep* 2006;8:492–500.
95. Robinson SM, Batelaan SF, Syddall HE, et al. Combined effects of dietary fat and birth weight on serum cholesterol concentrations: the Hertfordshire Cohort Study. *Am J Clin Nutr* 2006;84:237–44.
96. Ordovas JM. Nutrigenetics, plasma lipids, and cardiovascular risk. *J Am Diet Assoc* 2006;106:1074–81, quiz 1083.
97. Denke MA, Adams-Huet B, Nguyen AT. Individual cholesterol variation in response to a margarine- or butter-based diet: a study in families. *JAMA* 2000;284:2740–7.
98. Krauss RM, Dreon DM. Low-density-lipoprotein subclasses and response to a low-fat diet in healthy men. *Am J Clin Nutr* 1995;62(suppl):478S–87S.
99. Ordovas JM, Lopez-Miranda J, Mata P, Perez-Jimenez F, Lichtenstein AH, Schaefer EJ. Gene-diet interaction in determining plasma lipid response to dietary intervention. *Atherosclerosis* 1995;118(suppl):S11–27.
100. Dreon DM, Fernstrom HA, Miller B, Krauss RM. Apolipoprotein E isoform phenotype and LDL subclass response to a reduced-fat diet. *Arterioscler Thromb Vasc Biol* 1995;15:105–11.
101. German JB, Gibson RA, Krauss RM, et al. A reappraisal of the impact of dairy foods and milk fat on cardiovascular disease risk. *Eur J Nutr* 2009;48:191–203.
102. Rasmussen BM, Vessby B, Uusitupa M, et al. Effects of dietary saturated, monounsaturated, and n-3 fatty acids on blood pressure in healthy subjects. *Am J Clin Nutr* 2006;83:221–6.
103. Simons-Morton DG, Hunsberger SA, Van Horn L, et al. Nutrient intake and blood pressure in the Dietary Intervention Study in Children. *Hypertension* 1997;29:930–6.
104. Brinkworth GD, Noakes M, Buckley JD, Keogh JB, Clifton PM. Long-term effects of a very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 mo. *Am J Clin Nutr* 2009;90:23–32.
105. Niinikoski H, Jula A, Viikari J, et al. Blood pressure is lower in children and adolescents with a low-saturated-fat diet since infancy: the special turku coronary risk factor intervention project. *Hypertension* 2009;53:918–24.
106. Riccardi G, Giacco R, Rivellese AA. Dietary fat, insulin sensitivity and the metabolic syndrome. *Clin Nutr* 2004;23:447–56.
107. Rivellese AA, Maffettone A, Vessby B, et al. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects. *Atherosclerosis* 2003;167:149–58.
108. Kennedy A, Martinez K, Chuang CC, LaPoint K, McIntosh M. Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. *J Nutr* 2009;139:1–4.
109. Reynoso R, Salgado LM, Calderon V. High levels of palmitic acid lead to insulin resistance due to changes in the level of phosphorylation of the insulin receptor and insulin receptor substrate-1. *Mol Cell Biochem* 2003;246:155–62.
110. Marshall JA, Bessesen DH, Hamman RF. High saturated fat and low starch and fibre are associated with hyperinsulinaemia in a non-diabetic population: the San Luis Valley Diabetes Study. *Diabetologia* 1997;40:430–8.
111. Parker DR, Weiss ST, Troisi R, Cassano PA, Vokonas PS, Landsberg L. Relationship of dietary saturated fatty acids and body habitus to serum insulin concentrations: the Normative Aging Study. *Am J Clin Nutr* 1993;58:129–36.
112. Christiansen E, Schnider S, Palmvig B, Tauber-Lassen E, Pedersen O. Intake of a diet high in trans monounsaturated fatty acids or saturated fatty acids. Effects on postprandial insulinemia and glycemia in obese patients with NIDDM. *Diabetes Care* 1997;20:881–7.
113. Salmeron J, Hu FB, Manson JE, et al. Dietary fat intake and risk of type 2 diabetes in women. *Am J Clin Nutr* 2001;73:1019–26.
114. van Dam RM, Willett WC, Rimm EB, Stampfer MJ, Hu FB. Dietary fat and meat intake in relation to risk of type 2 diabetes in men. *Diabetes Care* 2002;25:417–24.
115. Manco M, Calvani M, Mingrone G. Effects of dietary fatty acids on insulin sensitivity and secretion. *Diabetes Obes Metab* 2004;6:402–13.
116. Vessby B, Unsitupa M, Hermansen K, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. *Diabetologia* 2001;44:312–9.
117. Howard BV. Dietary fat and diabetes: a consensus view. *Am J Med* 2002;113(suppl 9B):38S–40S.
118. Shi H, Kokoeva MV, Inouye K, Tzamei I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. *J Clin Invest* 2006;116:3015–25.
119. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. *J Biol Chem* 2001;276:16683–9.
120. Laine PS, Schwartz EA, Wang Y, et al. Palmitic acid induces IP-10 expression in human macrophages via NF-kappaB activation. *Biochem Biophys Res Commun* 2007;358:150–5.
121. Erridge C, Samani NJ. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. *Arterioscler Thromb Vasc Biol* 2009;29:1944–9.
122. Baer DJ, Judd JT, Clevidence BA, Tracy RP. Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study. *Am J Clin Nutr* 2004;79:969–73.
123. Mohanty P, Ghanim H, Hamouda W, Aljada A, Garg R, Dandona P. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. *Am J Clin Nutr* 2002;75:767–72.
124. Bellido C, Lopez-Miranda J, Blanco-Colio LM, et al. Butter and walnuts, but not olive oil, elicit postprandial activation of nuclear transcription factor kappaB in peripheral blood mononuclear cells from healthy men. *Am J Clin Nutr* 2004;80:1487–91.
125. Jimenez-Gomez Y, Lopez-Miranda J, Blanco-Colio LM, et al. Olive oil and walnut breakfasts reduce the postprandial inflammatory response in mononuclear cells compared with a butter breakfast in healthy men. *Atherosclerosis* 2009;204:e70–6.
126. Koren MS, Purnell JQ, Breen PA, Matthys CC, Callahan HS, Weigle DS. Plasma C-reactive protein concentration is not affected by isocaloric dietary fat reduction. *Nutrition* 2006;22:444–8.
127. Erlinger TP, Miller ER 3rd, Charleston J, Appel LJ. Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-sodium trial. *Circulation* 2003;108:150–4.
128. Han SN, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN. Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. *J Lipid Res* 2002;43:445–52.
129. Nanji AA, Zakim D, Rahemtulla A, et al. Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alpha and reverse fibrosis in alcohol-induced liver disease in the rat. *Hepatology* 1997;26:1538–45.
130. Seo T, Qi K, Chang C, et al. Saturated fat-rich diet enhances selective uptake of LDL cholesteryl esters in the arterial wall. *J Clin Invest* 2005;115:2214–22.
131. Nicholls SJ, Lundman P, Harmer JA, et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. *J Am Coll Cardiol* 2006;48:715–20.
132. Masterjohn C. The anti-inflammatory properties of safflower oil and coconut oil may be mediated by their respective concentrations of vitamin E. *J Am Coll Cardiol* 2007;49:1825–6.

